Transgene — developer of TG4050 (myvac), a viral-vector personalized neoantigen vaccine built on the myvac/NEC AI platform.
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC. Adjuvant treatment with the individualized, viral vector–based neoantigen vaccine TG4050 was safe and induced durable neoantigen-specific CD8-positiv…
Summit organizers frame the field at an inflection point: Moderna and Merck have reported positive initial Phase 3 data for intismeran autogene in combination with Keytruda, putting the first regulatory approval of a personalized neoantigen cancer vaccine firmly within sight. The 3rd Annual Personalized Cancer Vaccine Summit (December 1-3, 2026) draws 80+ leaders from Moderna, Medici Therapeutics, Geneos Therapeutics, Nykode Therapeutics, Echo Immune, HDT Bio, Mayo Clinic, and Transgene. The stated agenda — development, manufacturing, delivery, and market access — is a useful proxy for where the industry sees its next bottlenecks now that proof-of-concept is largely settled.
A DataM Intelligence press release forecasts the personalized cancer vaccines market reaching US$30.12 billion by 2033 at an 11.5% CAGR, naming Gritstone Bio, CureVac, and Transgene as key players. Treat the figures as directional: this is vendor-published via openPR, not peer-reviewed, with no methodology disclosed. The signal worth noting is continued third-party framing of personalized immunotherapy as a growth market through the next decade.
Personalized neoantigen vaccines are moving from early proof to later-stage clinical validation. In melanoma, Moderna and Merck’s mRNA vaccine intismeran, combined with pembrolizumab, met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in a phase 3 trial. In head and neck cancer, Transgene’s personalized vaccine TG4050 induced durable immune responses in a phase 1 trial, but efficacy remains unconfirmed. The contrast matters for investors: melanoma has a positive efficacy signal, while head and neck still requires confirmatory data.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected, HPV-negative HNSCC. TG4050, a modified Vaccinia Ankara (MVA) viral vector–based individualized neoantigen therapeutic vaccine encoding up to 30 …
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group All 16 patients treated with an individualized cancer vaccine after surgery for locally advanced head and neck cancer remained disease-free aft…
2026 Half-Year Results and Business Update myvac® - Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturing TG4050 - First Individualized Neoantigen Therapeutic Vaccine (INTV) from the myvac® platform adva…
Log in here to read the desired article. French biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a randomized Phase 1 trial remained disease-free after three years, while three of 16 patients in the control arm rel…
Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) among patients treated with the individualized neoantigen therapeutic vaccine TG4050 in the Phase 1 portion of a randomized Phase 1/2 trial in resected, locally advanced HPV-negative…
Transgene’s Individualized Neoantigen Therapeutic Cancer GlobeNewswire
January 09, 2026 02:00 ET | Source: Transgene S.A. Transgene S.A. TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, Franc…